Navigation Links
MannKind Corporation Response to Recent Market Events
Date:3/10/2008

VALENCIA, Calif., March 10 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today issued the following statement in response to recent market events:

MannKind is absolutely committed to the continued development of its lead development product, Technosphere(R) Insulin. We use our small, patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin to patients with diabetes in a way that much more closely matches the pattern of insulin secretion seen in people without disease. MannKind believes that the resulting efficacy and safety profile is unique and clearly differentiated from all existing diabetes treatments. To achieve normal glucose control, it is necessary to independently address both mealtime and fasting glucose. We believe Technosphere(R) Insulin is the only therapy that separately and independently lowers prandial glucose excursions, and that it will thus offer an important benefit to many patients with this devastating disease.

MannKind recognizes that in order to be successful in today's health care market a product must offer improved efficacy and safety, not just improved convenience. The decisions of Eli Lilly and Company as well as Pfizer and Novo Nordisk to discontinue the development of their inhaled insulin products reinforce this view. None of those products offer any advantages over injectable rapid acting insulin analogs.

By contrast, in clinical trials to date, Technosphere(R) Insulin has shown important advantages over the treatment that is presently considered to be the most effective meal-time therapy for patients -- rapid-acting insulin analogs. Specifically, Technosphere(R) Insulin has demonstrated:

-- A significant reduction in post-prandial glucose ex
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... how to produce ultra-thin "diamond nanothreads" that promise extraordinary ... today,s strongest nanotubes and polymers. A paper describing this ... Badding, a professor of chemistry at Penn State University, ... of the journal Nature Materials . , "From ... because the threads we formed have a structure that ...
(Date:9/20/2014)... September 20, 2014 HealthTronics, ... and interventional radiology products and services, has signed ... with Clinicon Corporation for its high ... portfolio of minimally invasive, mobile, surgical technology—offering more ... Under the agreement, HealthTronics will make available Clinicon’s ...
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... September 19, 2014 Follow ... potential to revolutionize the world has attracted diverse ... and small start-ups. The early years of nanotechnology ... largely due to the high risks involved, which ... earmarked for this evolving technology have been growing ...
Breaking Biology Technology:Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... Broadway Hotel in New York on Thursday, ... ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... Executive Officer, will present at,the NewsMakers in the Biotech Industry investment ...
... Belgium, August 24 ThromboGenics NV (Euronext,Brussels: THR), ... a business update and its financial results for ... this period, ThromboGenics has raised,additional funds to invest ... good progress with its clinical programs. Highlights ...
... Stem cell company,Neuralstem, Inc. (OTC Bulletin Board: NRLS) ... on the American Stock Exchange(R) (Amex(R)),under the symbol CUR. ... August 27, 2007. "Moving to the Amex is ... of the continuous and significant progress the company has ...
Cached Biology Technology:Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 4ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 5ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 6ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 7ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 8ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 9ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 10ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 11Neuralstem Shares Accepted for Trading on Amex(R) 2
(Date:9/21/2014)... T cells may have the ability to trigger an ... led by King,s College London. Although their immune system ... still be able to mount a strong immune defense, ... Medicine . , Our immune system is made up ... which play an important role in the frontline defense ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... you are a species which over thousands of years has ... to a substance that makes the cold dangerous for you. ... Enchytraeus albidus , and the cold provoking substance, called nonylphenol, ... , Nonylphenol is suspected of being a endocrine disruptor, but ... inhibits the worm,s ability to protect the cells in its ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... of Preventive Medicine (ACPM) has launched a web ... medicine the practice of changing health behaviors to ... The document summarizes scientific evidence supporting lifestyle interventions. ... such as definitions, reimbursement trends, related practice patterns, ...
... advent of the Human Genome Project an explosion of data ... demand to fine-tune genomic codes, which list the "ingredients for ... A Rutgers UniversityCamden biochemist is addressing this ... "background checks" on all known enzyme functions. Thanks to ...
... increases in obesity and associated diseases -- and fiery debates ... team has identified a new genetic mechanism that controls the ... to new treatments for obesity and type 2 diabetes, and ... people and dramatically cut health care costs. A research ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2Rutgers-Camden developing enzyme function database 2UCF discovery could open door to obesity, diabetes treatments 2
... The ProteoSpin Detergent Clean-up Micro Kit provides ... removal of SDS, Triton X-100 and other detergents ... spin-column chromatography using Norgens patented protein resin as ... processing 2 50 g of either acidic or ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... hematopoietic stem cells called monocytes. Osteoclasts resorb ... and lowering the surrounding pH to an ... mineral is then solubilized and the collagen ... primarily by Macrophage Colony-Stimulating Factor (M-CSF) and ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: